December 17, 2020 03:20 AM ESTUpdated 01:32 PM
Deals

Build­ing its neu­ro pipeline, No­var­tis antes up $210M cash to buy a biotech part­ner drug­ging 'both fla­vors' of NM­DA

Amber Tong

Af­ter J&J and Al­ler­gan shone a bright spot­light on the role of NM­DA re­cep­tors in psy­chi­atric dis­eases, No­var­tis has jumped in with both feet by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times